← back to search

Julen Oyarzábal

Universidad de Navarra · ES
Area of research
Molecular Biology · Computational Theory and Mathematics
Research interest
Research interests include Computational Drug Discovery Methods, Epigenetics and DNA Methylation, Histone Deacetylase Inhibitors Research, and Organophosphorus compounds synthesis.
h-index
44
citations
6,913
works
167
NIH funding
primary concept
Chemistry
email

Recent publications

Table S3 and S4 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Table S9 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Table S3 and S4 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Supplementary Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Data from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Data from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Supplementary Figures S1-S7 from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Table S10 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Table S1 and S2 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Supplementary Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Table S5, S6 and S7 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Supplementary Figures S1-S7 from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Table S10 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Table S1 and S2 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Data from Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death
2023cited by 0position: contributordoi
Table S5, S6 and S7 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
Table S9 from Zebrafish: Speeding Up the Cancer Drug Discovery Process
2023cited by 0position: contributordoi
CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage.
2022cited by 1position: contributordoi
Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death.
2021cited by 59position: contributordoi
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multiple Myeloma.
2021cited by 21position: contributordoi
Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology 2020cited by 66position: middledoi
Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach.
2020cited by 13position: contributordoi
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: <i>In Vivo</i> Evaluation in a Murine Model of Acute Pancreatitis.
2020cited by 13position: contributordoi
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.
2019cited by 152position: contributordoi
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.
2019cited by 100position: contributordoi
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
2019cited by 34position: contributordoi
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.
2019cited by 27position: contributordoi
Targeting CB<sub>1</sub> and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.
2019cited by 25position: contributordoi
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.
2019cited by 19position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 26 papers (2019–2023)Patricia Letrado · Universidad Complutense de Madrid12 papers (2023–2023)Irene de Miguel · Centro de Investigación Médica Aplicada12 papers (2023–2023) · 12 papers (2023–2023)Felipe Prosper · Universidad de Málaga11 papers (2019–2023)Puri Fortes · Navarre Institute of Health Research8 papers (2019–2023)Maria-Jose Garcia-Barchino · Centro de Investigación Biomédica en Red de Cáncer7 papers (2021–2023)Marta Larrayoz · Chartered Institute of Management Accountants7 papers (2021–2023)Alexandra Junza · Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition7 papers (2021–2023)Jon Celay · 7 papers (2021–2023)María J. Moreno-Aliaga · University of Pamplona7 papers (2021–2023)Carmen Vicente · Centro de Investigación Biomédica en Red de Cáncer7 papers (2021–2023) · 7 papers (2021–2023)Maria-Dolores Odero · Instituto de Salud Carlos III7 papers (2021–2023)Rubén Pı́o · Navarre Institute of Health Research7 papers (2021–2023)Antonio Pineda-Lucena · Tulane University3 papers (2019–2021)Obdulia Rabal · Harvard University2 papers (2019–2020)Xabier Agirre · Instituto de Salud Carlos III2 papers (2019–2019) · 1 papers (2015–2015)Stefano Caruso · Université Paris-Est Créteil1 papers (2019–2019)